Share capital [Text Block] | 10. Share capital Authorized share capital Unlimited number of common shares without par value. Issued share capital On August 28, 2017, the Company consolidated its common shares on a basis of one (1) new common share for two (2) old common shares held. Reference to common shares, per share amounts and other securities have been retroactively restated. At December 31, 2017 there were 40,664,015 issued and fully paid common shares (2016 – 21,537,349). Financings During the year ended December 31, 2017, the following equity financings were completed: I) On August 30, 2017, the Company closed a private placement of 8,333,333 units at a price of $0.06 per unit for gross proceeds of $500,000. Each unit consists of one common share and one share purchase warrant exercisable into one common share at a price of $0.07 during the first year and $0.08 during years two and three. The Company used the residual method to value the share purchase warrants, allocating a value of $nil. As part of the private placement, the Company incurred other cash issuance costs of $4,575. II) On October 24, 2017, the Company closed a private placement of 6,750,000 units at a price of $0.35 per unit for gross proceeds of $2,362,500. Each unit consists of one common share and one half of one share purchase warrant. Each whole warrant is exercisable into one common share at a price of $0.45 with an expiry date of three years after the closing date. The Company used the residual method to value the share purchase warrants, allocating a value of $nil. As part of the private placement, the Company paid $126,313 in finder’s fees and other cash issuance costs of $16,663. In addition, the Company issued 396,000 in broker warrants with an expiry date of one year after the closing date. The fair value of $111,210 for the broker warrants was estimated using the Black-Scholes Option Pricing Model and was charged to share issue costs and credited to contributed surplus. The assumptions used in the Black-Scholes Option Pricing Model were as follows: share price of $0.54 ; exercise price of $0.35 ; expected volatility of 100%; expected life of 1 year; a risk-free interest rate of 0.73%; and an expected dividend rate of nil. III) On December 20, 2017, the Company closed a private placement of 1,813,333 units at a price of $0.60 per unit for gross proceeds of $1,088,000. Each unit consists of one common share and one half of one share purchase warrant. Each whole warrant is exercisable into one common share at a price of $0.70 with an expiry date of three years after the closing date. The Company used the residual method to value the share purchase warrants, allocating a value of $36,267. As part of the private placement, the Company paid $59,160 in finder’s fees and other cash issuance costs of $2,306. In addition, the Company issued 98,600 in broker warrants with an expiry date of one year after the closing date. The fair value of $18,762 for the broker warrants was estimated using the Black-Scholes Option Pricing Model and was charged to share issue costs and credited to contributed surplus. The assumptions used in the Black-Scholes Option Pricing Model were as follows: share price of $0.58 ; exercise price of $0.70 ; expected volatility of 100%; expected life of 1 year; a risk-free interest rate of 0.73%; and an expected dividend rate of nil. IV) On December 27, 2017, the Company closed a private placement of 1,250,000 units at a price of $0.60 per unit for gross proceeds of $750,000. Each unit consists of one common share and one half of one share purchase warrant. Each whole warrant is exercisable into one common share at a price of $0.70 with an expiry date of three years after the closing date. The Company used the residual method to value the share purchase warrants, allocating a value of $nil. As part of the private placement, the Company paid $45,000 in finder’s fees and other cash issuance costs of $3,050. In addition, the Company issued 75,000 in broker warrants with an expiry date of one year after the closing date. The fair value of $22,333 for the broker warrants was estimated using the Black-Scholes Option Pricing Model and was charged to share issue costs and credited to contributed surplus. The assumptions used in the Black- Scholes Option Pricing Model were as follows: share price of $0.74 ; exercise price of $0.70 ; expected volatility of 100%; expected life of 1 year; a risk-free interest rate of 0.73%; and an expected dividend rate of nil. During the year ended December 31, 2016, the following equity financings were completed: I) In March 2016, the Company closed a private placement of 9,120,000 units at a price of $0.02 per unit for gross proceeds of $182,400. Each unit consists of one common share and one share purchase warrant exercisable into one common share at a price of $0.10 for a period of five years after the closing date. The Company did not separately value the warrants issued as part of this private placement. Included in the private placement were 2,700,000 shares issued to officers and directors of the Company. As part of the private placement, the Company paid $1,800 in finder’s fees and issued 90,000 in broker warrants with an expiry date of one year after the closing date. The Company determined that the value of the broker warrants was insignificant. II) In April 2016, the Company closed a private placement of 3,380,000 units at a price of $0.02 per unit for gross proceeds of $67,600. Each unit consists of one common share and one share purchase warrant exercisable into one common share at a price of $0.10 for a period of five years after the closing date. The Company did not separately value the warrants issued as part of this private placement. As part of the private placement, the Company paid $2,816 in finder’s fees and issued 10,800 in broker warrants with an expiry date of one year after the closing date. The Company determined that the value of the broker warrants was insignificant. Basic and diluted loss per share The calculation of basic and diluted loss per share for the year ended December 31, 2017 was based on the loss attributable to common shareholders of $683,299 (2016 - $224,112) and the weighted average number of common shares outstanding of 25,986,111 (2016 – 18,347,211). Diluted loss per share did not include the effect of 2,662,500 stock options and 25,454,600 warrants as the effect would be anti-dilutive. Stock options The Company has adopted an incentive stock option plan, which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the Exchange requirements, grant to directors, officers, employees and technical consultants to the Company, non-transferable stock options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the Company’s issued and outstanding common shares. Such options will be exercisable for a period of up to 5 years from the date of grant. In connection with the foregoing, the number of common shares reserved for issuance to any one optionee will not exceed five percent ( 5%) of the issued and outstanding common shares and the number of common shares reserved for issuance to all investor relations and technical consultants will not exceed two percent ( 2%) of the issued and outstanding common shares. Options may be exercised no later than 90 days following cessation of the optionee’s position with the Company or 30 days following cessation of an optionee conducting investor relations activities’ position. On exercise, each option allows the holder to purchase one common share of the Company. The changes in options during the years ended December 31, 2017 and 2016 are as follows: Year ended Year ended December 31, 2017 December 31, 2016 Weighted Weighted average average Number of exercise Number of exercise options price options price Options outstanding, beginning 1,640,000 $ 0.19 234,700 $ 2.16 Options granted 1,150,000 0.50 1,475,000 0.10 Options exercised (125,000 ) 0.10 - - Options expired/forfeited (2,500 ) 1.00 (69,700 ) 4.88 Options outstanding, ending 2,662,500 $ 0.33 1,640,000 $ 0.19 Options exercisable, ending 2,602,500 $ 0.32 902,500 $ 0.26 The weighted average share price on the date of option exercise during the year ended December 31, 2017 was $0.56. Details of options outstanding as at December 31, 2017 are as follows: Weighted average Weighted average Number of options exercise price contractual life outstanding $1.00 0.01 years 162,500 $0.10 3.50 years 1,350,000 $0.22 4.70 years 100,000 $0.40 4.76 years 550,000 $0.60 4.81 years 325,000 $0.80 4.87 years 175,000 $0.33 3.50 years 2,662,500 Stock-based compensation During the year ended December 31, 2017, the Company granted 1,150,000 stock options (2016 – 1,475,000 stock options), the weighted average grant date fair value of the options was $0.32 per option (2016 - $0.04 per option). The fair value was determined using the Black-Scholes option pricing model using the following weighted average assumptions: 2017 2016 Share price $0.44 $0.06 Exercise price $0.50 $0.10 Expected life of options 5 years 5 years Annualized volatility 100% 102% Risk-free interest rate 1.60% 0.62% Dividend rate 0% 0% During the year ended December 31, 2017, the Company recorded $360,493 (2016 - $42,831) of stock-based compensation to the statement of loss and comprehensive loss based on the vesting of stock options granted. Warrants On exercise, each warrant allows the holder to purchase one common share of the Company. The changes in warrants outstanding during the years ended December 31, 2017 and 2016 are as follows: Year Year ended December 31, 2017 December 31, 2016 Average Average Number of exercise Number of exercise warrants price warrants price Warrants outstanding, beginning 13,444,147 $ 0.10 1,052,680 $ 0.24 Warrants issued 13,809,600 0.25 12,600,800 0.10 Warrants exercised (855,000 ) 0.06 - - Warrants expired (944,147 ) 0.10 (209,333 ) 0.80 Warrants outstanding, ending 25,454,600 $ 0.18 13,444,147 $ 0.10 Details of warrants outstanding as at December 31, 2017 are as follows: Weighted average Weighted average Number of warrants exercise price contractual life outstanding $0.35 0.81 years 396,000 $0.70 0.98 years 173,600 $0.07 2.67 years 7,583,333 $0.45 2.82 years 3,375,000 $0.70 2.98 years 1,531,667 $0.10 3.27 years 12,395,000 $0.18 2.95 years 25,454,600 Refer to Note 17 – Subsequent Events. |